BridgeBio Oncology Therapeutics BBOT
NASDAQ BBOT
$3.92 +0.11 (+2.89%)
At close: Sep 29, 2026 · 4:00 PM EDT

BridgeBio Oncology Therapeutics (BBOT) Total Debt (2023 - 2026)

Updated

BridgeBio Oncology Therapeutics (BBOT) posted Total Debt of $716,000 for Q1 2026, up 721.3% from $87,183 a year earlier and up 34.1% from the prior quarter.

Analysis

BridgeBio Oncology Therapeutics (BBOT) Total Debt (2023 - 2026) Analysis & Trends

At the end of FY2025, BridgeBio Oncology Therapeutics' Total Debt came in at $534,000, up 10.6% from FY2024.

  • In prior years, BridgeBio Oncology Therapeutics' Total Debt was $483,000 in FY2024 (+589.1%) and $70,095 in FY2023.
  • According to Business Quant data, Total Debt for the three prior quarters was $534,000 (Q4 2025), $691,000 (Q3 2025) and $106,557 (Q2 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 49.04 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 70.82 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 53.91 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 37.49 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -111.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 57.30 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 26.25 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 63.19 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 BridgeBio Oncology Therapeutics 305.24 Mn -1.07 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 716,000.00
Dec 31, 2025 534,000.00
Sep 30, 2025 691,000.00
Jun 30, 2025 106,557.00
Mar 31, 2025 87,183.00
Dec 31, 2024 483,000.00
Dec 31, 2023 70,095.00
API Access

BridgeBio Oncology Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=BBOT&period=max&api_key=YOUR_API_KEY